FDA Gives Tocilizumab Priority Review Status for Giant Cell Arteritis

FDA Gives Tocilizumab Priority Review Status for Giant Cell Arteritis

FDA will fast track review of nonsteroidal treatment option for giant cell arteritis.

Increased VTE Risk in GCA With and Without Glucocorticoids

Increased VTE Risk in GCA With and Without Glucocorticoids

Patients experienced an elevated risk of venous thromboembolism both immediately before and immediately after giant cell arteritis diagnosis.

Rituximab Decreases Malignancy Risk in ANCA-Associated Vasculitis

Rituximab Decreases Malignancy Risk in ANCA-Associated Vasculitis

A retrospective analysis has shown that patients with ANCA-associated vasculitis treated with rituximab have a much lower risk of developing subsequent malignancies when compared with those treated with cyclophosphamide.

New-Onset Diabetes Risk in Giant Cell Arteritis With Prednisone

New-Onset Diabetes Risk in Giant Cell Arteritis With Prednisone

Treatment of giant cell arteritis or granulomatosis with polyangiitis with prednisolone or prednisone has been linked to elevated risks of type 2 diabetes early during treatment.

Tocilizumab Granted Breakthrough Therapy Designation by FDA for GCA

Tocilizumab Granted Breakthrough Therapy Designation by FDA for GCA

Tocilizumab (Actemra®,Genentech) is the first treatment proposed for giant cell arthritis in 50 years.

Shared Etiologic Inflammatory Link in Pediatric KD, Adult KLS

Shared Etiologic Inflammatory Link in Pediatric KD, Adult KLS

Distinctive presentations, histopathology, and therapeutic response in both KD and KLS suggest a common etiology.

Incidence of VTE, Stroke in GCA and Non-GCA Comparators

Incidence of VTE, Stroke in GCA and Non-GCA Comparators

Retrospectively acquired population-based data suggest that the incidence of VTE, stroke and TIA was similar in patients with GCA compared to those who did not have GCA.

Is Post-Vaccination IgG Predictive of Mortality in Systemic Vasculitis?

Is Post-Vaccination IgG Predictive of Mortality in Systemic Vasculitis?

Low IgG and B cell counts were associated with infection and vaccine response among patients with systemic vasculitis in stable remission.

Biomarkers Prognostic of Immunosuppression Side Effects in Vasculitis

Biomarkers Prognostic of Immunosuppression Side Effects in Vasculitis

Measuring IgG levels and B cell counts may identify high infection risk and help clinicians balance the risk of immunosuppression side effects and disease activity in patients with systemic vasculitis.

Can Tocilizumab Be Steroid-Sparing While Maintaining Remission in GCA?

Can Tocilizumab Be Steroid-Sparing While Maintaining Remission in GCA?

This is the first randomized placebo-controlled trial to demonstrate the induction and remission efficacy of IL-6 inhibition with tocilizumab in patients with giant cell arteritis (GCA).

Sign Up for Free e-newsletters